-- Weebit Nano（ASX:WBT）は、同社の抵抗変化型ランダムアクセスメモリ（ReRAM）技術を統合したチップ設計のテープアウトを2社の顧客企業が成功裏に完了したと発表した。これは、商用規模生産に向けた重要な一歩となる。同社は月曜日にオーストラリア証券取引所に提出した書類で明らかにした。 提出書類によると、Overlord Labs社は同社のReRAMを次世代スマートバッテリー管理システムに組み込み、DB HiTek社でテープアウトを完了した。電力効率の向上、コスト削減、そして大量生産における性能向上を目指している。 また、別の顧客企業は既にプロトタイプの初期シリコンを受け取っており、ReRAMコンポーネントを含め、期待通りに動作していると書類には記載されている。 両プロジェクトは現在、長期テスト、特性評価、および認定段階に入っており、量産開始までには12～18ヶ月かかる見込みだと書類は付け加えている。 同社の株価は、月曜日の取引で約7%上昇した。
Related Articles
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Stryker Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $360 from $438, 21.5x our 2027 EPS forecast, below SYK's 10-year historical average of 24.5x. We maintain our 2026 EPS forecast at $14.94 and our 2027 EPS estimate at $16.71. We think that Stryker's Q1 results were significantly impacted by the late-quarter cyber incident that caused global business disruptions, leading to a miss on both revenue and earnings estimates. Despite disruptions affecting manufacturing, shipments, and revenue recognition, management maintained the full-year 2026 guidance of 8% to 9.5% Y/Y organic sales growth and adjusted EPS in the range of $14.90 to $15.10, expecting to recover most lost sales, which we find encouraging. Key catalysts for the remainder of the year include the proposed acquisition of Amplitude Vascular Systems, which has the potential to expand Stryker's cardiovascular capabilities and the creation of a new Ortho Tech business, which could streamline innovation and customer experience, in our view.
$SYK
International
Philippine Manufacturing Activity Contracts as Orders Fall, Costs Rise, S&P Global Says
The Philippines' manufacturing sector slipped into contraction in April as new orders fell sharply and cost pressures intensified, according to data released Monday by S&P Global.The S&P Global Philippines Manufacturing Purchasing Managers' Index fell to 48.3 in April from 51.3 in March, marking the first contraction since November.New orders declined at the fastest pace since August 2021, while export demand weakened further, with firms citing trade route disruptions and halted shipments.Production stalled, and firms cut employment and purchasing activity, drawing down inventories to meet output needs.Input costs rose at the fastest pace since December 2022, driven by higher energy and shipping costs linked to the Middle East war, prompting the sharpest increase in selling prices in 41 months.Supplier delivery times lengthened, while business confidence improved to a 17-month high on expectations of stronger demand ahead.
$^PSEi
Research
Research Alert: CFRA Maintains Hold View On Shares Of Ametek, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following AME's Q1 beat, we lift our 12-month target to $260 from $240, valuing shares at 29.5x our 2027 EPS outlook of $8.81 (up $0.20; 2026 EPS outlook lifted to $8.12 from $8.00), above AME's five-year historical multiple average given a strengthening earnings growth trajectory. Notably, AME experienced a Q1 acceleration in demand, highlighted by record orders of $2.2 billion, representing 22% organic growth and leading to a record backlog of $3.87 billion. This growth was broad-based, with sustained strength in Aerospace & Defense and a notable inflection in orders for the more cyclical Process and Power businesses. Profitability also was a positive, as core operating margins expanded by 160 basis points, driven by volume leverage in the Electromechanical Group (EMG). Overall, Q1 results were encouraging though shipment delays stemming from conflict in the Middle East was a modest headwind, indicating that spillover effects could become a bigger headache if instability in the region worsens.
$AME